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Background: Inhaled corticosteroids provide unique systems for local treatment of asthma or 
chronic obstructive pulmonary disease. However, the use of poorly soluble drugs for nebuliza-
tion has been inadequate, and many patients rely on large doses to achieve optimal control of 
their disease. Theoretically, nanotechnology with a sustained-release formulation may provide 
a favorable therapeutic index. The aim of this study was to determine the feasibility of using 
sterically stabilized phospholipid nanomicelles of budesonide for pulmonary delivery via 
nebulization.
Methods: PEG5000-DSPE polymeric micelles containing budesonide (BUD-SSMs) were 
prepared by the coprecipitation and reconstitution method, and the physicochemical and phar-
macodynamic characteristics of BUD-SSMs were investigated.
Results: The optimal concentration of solubilized budesonide at 5 mM PEG5000-DSPE was 
605.71 ± 6.38 µg/mL, with a single-sized peak population determined by photon correlation 
spectroscopy and a particle size distribution of 21.51 ± 1.5 nm. The zeta potential of BUD-SSMs 
was −28.43 ± 1.98 mV . The percent entrapment efficiency, percent yield, and percent drug loading 
of the lyophilized formulations were 100.13% ± 1.09%, 97.98% ± 1.95%, and 2.01% ± 0.02%, 
respectively. Budesonide was found to be amorphous by differential scanning calorimetry, and 
had no chemical interaction with PEGylated polymer according to Fourier transform infrared 
spectroscopy. Transmission electron microscopic images of BUD-SSMs revealed spherical 
nanoparticles. BUD-SSMs exhibited prolonged dissolution behavior compared with Pulmicort 
Respules® (P , 0.05). Aerodynamic characteristics indicated significantly higher deposition in the 
lungs compared with Pulmicort Respules®. The mass median aerodynamic, geometric standard 
deviation, percent emitted dose, and the fine particle fraction were 2.83 ± 0.08 µm, 2.33 ± 0.04 µm, 
59.13% ± 0.19%, and 52.31% ± 0.25%, respectively. Intratracheal administration of BUD-SSMs 
23 hours before challenge (1 mg/kg) in an asthmatic/chronic obstructive pulmonary disease rat 
model led to a significant reduction in inflammatory cell counts (76.94 ± 5.11) in bronchoalveolar 
lavage fluid compared with administration of Pulmicort Respules® (25.06 ± 6.91).
Conclusion: The BUD-SSMs system might be advantageous for asthma or chronic obstructive 
pulmonary disease and other inflammatory airway diseases.
Keywords: micelles, PEGylated polymer, aerodynamics, pharmacodynamics
Introduction
Asthma, chronic obstructive pulmonary disease, and other pulmonary diseases can be 
efficiently treated via the pulmonary route if high and prolonged drug concentrations 
are maintained in the lungs.1,2 Local treatment of lung disorders via pulmonary drug 
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delivery offers many advantages over oral or intravenous 
routes of administration, because direct deposition of drug 
at the diseased site could increase local drug concentrations, 
improve the pulmonary receptor occupancy, and reduce the 
overall dose required and the side effects that result from high 
doses of drug.3 In addition, sustained-release formulations 
for pulmonary delivery may result in a favorable therapeutic 
index by prolonging drug action at the target site, reducing 
its side effects, and enhancing patient compliance.4
Microparticle and nanoparticle drug carrier systems have 
been extensively studied.3,5–8 However, the majority of these 
formulations have not successfully controlled the inhaled ther-
apeutics in the pulmonary system for more than a few hours 
due to efficient clearance of the therapeutics from the deep 
lung either through phagocytosis or via the rapid absorption 
of the delivered therapeutics by the alveoli, making them more 
suitable for enhancing systemic bioavailability.4,9 Controlling 
the drug in the respiratory tract may be achievable by employ-
ing suitable carrier systems with appropriate drug-release 
characteristics. Among these drug carrier systems, polymeric 
micelles are particularly promising and are receiving increas-
ing attention.10,11 So-called polymeric micelle colloidal disper-
sions are self-assembled core-shell nanostructures formed in 
an aqueous solution consisting of hydrophobic fragments of 
amphiphilic molecules forming the core of a micelle, which 
is segregated from the environment by hydrophilic parts of 
the molecules that form the micelle corona.12,13 The cargo 
space (core) formed from the hydrophobic segment solubi-
lizes a variety of poorly soluble therapeutic and diagnostic 
agents. This solubilization increases the bioavailability and 
circulation time after parenteral administration, as well as 
modifying the pharmacokinetics and biodistribution of the 
therapeutic agents.14,15 The small size of the micelles permits 
their extravasation and accumulation in a variety of pathologi-
cal sites such as tumors.16 Additionally, polymeric micelles 
are easily prepared on a large scale.14
A variety of block copolymers may be used to form 
polymeric micelles, including conjugates of polyethylene 
glycol and phosphatidylethanolamine (PEG-DSPE), to form 
so-called sterically stabilized phospholipid nanomicelles 
(SSMs).17 Polymeric micelles have the ability to prolong 
the circulation time (in vivo experiments) and the ability 
to accumulate in target organs.18 In addition, the fact that 
humans secrete phospholipase A2, which is able to degrade 
PEG-DSPE, makes them biodegradable.19
However, to date, no in vitro or in vivo study of the 
efficiency of sterically stabilized phospholipid   nanomicelles 
containing a poorly water-soluble corticosteroid drug 
(  budesonide) as a pulmonary delivery system has been 
reported. Therefore, this study focused on the formulation, 
characterization, and in vitro and in vivo evaluation of steri-
cally stabilized phospholipid nanomicelles containing budes-
onide as a pulmonary delivery system via nebulization.
Materials and methods
Materials
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy-poly(ethylene glycol 5000) (PEG5000-DSPE) was 
purchased from NOF Corporation (Tokyo, Japan) and budes-
onide (molecular weight 430.50 g/mol) was purchased from 
Symbiotica Specialty Ingredients Sdn Bhd (Kedah, Malaysia). 
High-pressure liquid chromatography (HPLC)-grade metha-
nol and chloroform were purchased from Fisher Scientific 
(Franklin Lakes, NJ, and Leicestershire, UK, respectively). 
Phosphate-buffered saline tablets were purchased from 
Sigma-Aldrich Chemie Gmbh (Steinheim, Germany).
Preparation of BUD-SSMs
Aqueous dispersions of BUD-SSMs were prepared by the 
coprecipitation and reconstitution method using some modifica-
tions, as previously reported.20 Known amounts of budesonide 
and PEG5000-DSPE were mixed at different molar ratios. The 
mixtures were subsequently sonicated for 2 minutes using a 
sonicator processor (Bransonic Ultrasonic 8510, Danbury, CT). 
The content was transferred to a 50 mL round-bottomed flask, 
mixed, and vortexed for one minute. The organic solvents were 
evaporated under vacuum at 40°C using a rotary evaporator 
(Eyela N-1001S-W, Tokyo, Japan). Any traces of remaining 
solvent in the film obtained were removed under vacuum 
overnight.21 The dried films were rehydrated with phosphate-
buffered saline, and the SSMs were formed by shaking at 40°C 
for 10 minutes. Drug that was not encapsulated was separated 
by filtration of the micellar solutions using a 0.2 µm Minisart 
microfilter (Sartorius, Germany). The maximum solubility 
of budesonide in the SSMs was determined by keeping the 
PEG5000-DSPE concentration fixed (5 mM) and changing the 
drug concentration (budesonide to PEG5000-DSPE molar ratios 
ranged from 0.20 to 0.34) until a homogeneous system was 
confirmed by photon correlation spectroscopy as a single-
size peak population using a Zetasizer (Malvern 1000HSA, 
Worcestershire, UK). The amount of solubilized budesonide 
in the SSMs was determined spectrophotometrically using 
an ultraviolet spectrophotometer (Hitachi, model U-2000, 
Japan) at 244 nm after diluting the clear aqueous dispersion 
with methanol (drug-SSMs:methanol, 1:3 [v/v]). BUD-SSMs 
with the maximum solubility of budesonide were lyophilized 
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(Labconco 7753501, Labconco Corporation, Kansas City, MO) 
to form a lyophilized cake ready for reconstitution.
Physicochemical characterization  
of BUD-SSMs
The following parameters of the BUD-SSM formulations 
were characterized: particle size, using a Zetasizer (Malvern 
1000HSA); zeta potential, using a Zeecom zeta potential 
analyzer (Symphotic TII Corporation, Camarillo, CA); and 
entrapment efficiency (%EE), yield percentage (%Y), and 
drug loading percentage (%DL) using the following equa-
tions according to a previously published method:22
  %% EE
a
b
= 
 

  × 100
 
(1)
where (a) is the concentration of drug loaded in SSMs 
(µg/mL) and (b) is the amount of drug used in SSMs prepa-
ration (µg/mL):
 %Y =
Weight of the nanoparticles
Weight of the feeding polymer r and drug

 

  × 100% 
 
(2)
  %DL =
Weight of the drug in nanoparticles
Weight of the nanopa articles

 

  × 100%  
 
(3)
We also performed Fourier transform infrared spectros-
copy using an infrared spectrophotometer (Thermo Nicolet 
Corporation, Nexus model, Madison, WI), equipped with 
OMNIC 6.1 version software, differential scanning calorim-
etry (Perkin Elmer, Pyris 6, Boston, MA), and morphological 
examinations of the rehydrated BUD-SSMs using a transmis-
sion electron microscope (Phillips CM12, Eindhoven, The 
Netherlands) with Docu version 3.2 image analysis.
Solubility and dissolution study
To determine the sink condition, the solubility of budesonide 
in phosphate-buffered saline was measured by placing an 
excess amount of budesonide (300 mg) into 5 mL of phos-
phate-buffered saline (pH 7.4) in a dialysis bag (Spectra/pro, 
molecular weight cutoff 10,000 kD, Spectrum, Torrance, CA) 
placed in a 100 mL phosphate-buffered saline Pyrex bottle 
and shaken horizontally at 100 rpm in a thermostatic water 
bath (Memmrete WB22, Germany) at 37°C ± 0.5°C. Samples 
of the drug solution were withdrawn from the bottle (200 µL, 
after 30 hours) and analyzed by a validated HPLC method, 
as previously described.23 The resulting equilibrium drug 
concentration was used to calculate the saturated solubility 
drug concentration.24
For the dissolution study, rehydrated BUD-SSMs or 
Pulmicort Respules® (containing the equivalent amount of 
budesonide [400 µg] required for the sink condition) were 
diluted in 5 mL of phosphate-buffered saline (pH 7.4) and 
transferred into a dialysis bag. The two ends of the dialysis bag 
were fastened securely with special clips spaced 5 cm apart. 
The dialysis bag was placed into a Pyrex screw-capped bottle 
containing 100 mL of phosphate-buffered saline (pH 7.4) as 
the dissolution medium and 0.02% of sodium azide (Sigma-
Aldrich Chemie Gmbh) to prevent microbial growth. The 
bottle was shaken horizontally at 100 rpm in a thermostatic 
water bath (Memmrete WB22, Germany) at 37°C ± 0.5°C. At 
predetermined time intervals, 200 µL samples were withdrawn 
from the bottle and analyzed by a validated HPLC method, 
as described previously.23 Briefly, the system consisted of a 
Shimadzu LC-20AD delivery pump (Shimadzu, Tokyo, Japan) 
equipped with a SIL-20A HT prominence autosampler (Shi-
madzu) fitted with a 100 µL sample loop, an ultraviolet-visible 
detector (SPD-20A, Shimadzu), a DGU-20A3 prominence 
degasser (Shimadzu), and a chromato-integrator (CBM-20A 
prominence Communications Bus Model, Shimadzu). The 
chromatographic separation of the analyte was performed at 
40°C (CTO-10AS VP, Shimadzu column oven) using a Zor-
bax Eclipse Plus (250 × 4.6 mm, 5 mm) analytical column 
connected to a SecurityGuard™ cartridge system (Zorbax, 
Agilent Technologies, Colorado Springs, CO). The mobile 
phase consisted of 10 mM ammonium acetate (pH 5, adjusted 
with orthophosphoric acid) to acetonitrile (37:63). The mobile 
phase was filtered through a 0.45 µm nylon membrane filter 
(Whatman, Maidstone, UK) under vacuum and degassed prior 
to use. The analysis was conducted at a flow rate of 1.0 mL/
minute at an ultraviolet detection wavelength of 254 nm. The 
injection volume was 50 µL.
The kinetics of drug release were examined using the 
previously described add-in DDSolver program.25 Different 
mathematical kinetic models (zero-order, first order, Higuchi, 
Hixson-Crowell, and Baker-Lonsdale) were used to deter-
mine the drug release kinetics. The criteria for selecting the 
most appropriate model were based on the goodness of fit 
(adjusted coefficient of determination, R2 adjusted) and the 
Akaike information criterion.26
Aerodynamic characterization
In vitro deposition was investigated using a next generation 
impactor (Model 170) connected to a vacuum pump (HCP4) 
and Pari LC nebulizer (Pari LC plus nebulizer connected to an 
airjet compressor Pari Master type 84G73, Munich, Germany). 
A flow meter (DFM2) (Copley Scientific, UK) was used to 
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calibrate the airflow through the next generation impactor. 
Two mL of an aqueous preparation containing 0.5 mg of 
rehydrated BUD-SSMs was nebulized for 15   minutes at a 
room temperature of 28°C and a relative humidity of 65%. 
The effective cutoff diameters for the impactor at a flow 
rate of 60 L/min were: 8.06 µm (stage 1), 4.46 µm (stage 2), 
2.82 µm (stage 3), 1.66 µm (stage 4), 0.94 µm (stage 5), 
0.55 µm (stage 6), and 0.34 µm (stage 7). The flow rate of 
60 L/minute simulated the mean peak inspiratory flow rate 
of adult asthmatic patients.27 Each stage of the next genera-
tion impactor, the induction port, and the inhaler device were 
rinsed with 10 mL of the respective HPLC mobile phase and 
collected for quantitative analysis by HPLC.23
The mass median aerodynamic diameter and geometric 
standard deviation were calculated after plotting the cumula-
tive amount of drug under size deposited in each stage of the 
cascade impactor versus their corresponding aerodynamic 
diameter as specified by the cascade impactor using log-
probability paper.28 On this graph, the mass median aero-
dynamic diameter of the aerosolized particles is the particle 
size at which the line crosses the 50% mark (mass median 
aerodynamic diameter [µm] = D50%).
From a log-normal distribution that is normal with respect 
to aerodynamic diameter,28 the geometric standard deviation 
(GSD) becomes:
  GSD
undersize
undersize
= 
 

 
84 1
15 9
.%
.%
 
(4)
The emitted dose (ED) was determined as the percentage 
of total amount of drug available for nebulization:23,27
 
ED =
Amount of drug recovered in the cascade impactor
Amount o of drug initially loaded in the device

 

 
× 100%
 
 
(5)
The fine particle fraction was calculated as the total amount 
of drug deposited on Stage 2 or 3 to filter:23,27,29
 
FPF=
Amount of drug recovered from stage 2 or 3 to filter
Amo ount of drug initially loaded in the device

 

 
×100%
 
 
(6)
Inhibitory duration of inflammatory cell  
infiltration in airways after BUD-SSMs  
and Pulmicort Respules®
The experimental protocol (see Scheme 1) was designed 
to study the duration of budesonide inhibition with respect 
to total cell counts and differential cell counts in the 
bronchoalveolar lavage fluid of ovalbumin-sensitized and 
  ovalbumin-challenged male Sprague-Dawley rats. The pro-
tocol for ovalbumin sensitization and challenge (Scheme 1) 
was modified from a previously published method.30 The 
experimental protocol was approved by the Animal Ethics 
Committee, Health Campus, Universiti Sains Malaysia. 
Pathogen-free male Sprague-Dawley rats (8–11 weeks of 
age) weighing 200 ± 50 g, were housed six per cage in the 
laboratory with free access to food and water, and maintained 
on a 12-hour dark/light cycle. Briefly, following acclima-
tization, the rats were randomly divided into four groups: 
Group A, untreated rats, required to illustrate and define the 
physiological norm of inflammatory cell infiltration (con-
trols); Group B, rats sensitized by intraperitoneal injection of 
100 µg ovalbumin precipitated in 5 mg aluminum hydroxide 
(ovalbumin precipitate) per rat on days 0, 7, and 14 (nega-
tive control) and used to assess the effect of sensitization on 
inflammatory cell infiltration; Group C rats, sensitized by 
intraperitoneal injection of 100 µg ovalbumin precipitate on 
days 0, 7, and 14, followed by anesthesia and intratracheal 
instillation of ovalbumin challenge (100 µg/rat) 24 hours 
after the last ovalbumin sensitization, ie, on day 14 (positive 
control), and used to assess the effect of ovalbumin chal-
lenge on inflammatory cell infiltration; and Group D, which 
comprised the treatment group, and was divided into nine 
subgroups as follows:
•	 Pulmicort Respules® group, in which treatment was 
administered via intratracheal instillation 23 hours (DP1), 
12 hours (DP2), or one hour (DP3) before ovalbumin 
challenge.
•	 BUD:PEG5000-DSPE SSMs group (F43, A, interven-
tion group, n = 18) in which treatment was adminis-
tered via intratracheal instillation 23 hours (DIA1), 
12 hours (DIA2), or one hour (DIA3) before ovalbumin 
challenge.
•	 Rehydrated PEG5000-DSPE SSMs group (F39), in which 
treatment was administered via intratracheal instillation 
one hour (D1) before ovalbumin challenge to examine 
the pharmacodynamic effect of the placebo treatment on 
the ovalbumin model rats.
Rats were sensitized by intraperitoneal injection of 
100 µg/rat ovalbumin with 5 mg aluminum hydroxide on 
days 0, 7, and 14. They were anesthetized by intraperito-
neal injection of ketamine + xylazine (80 mg/kg + 8 mg/
kg intraperitoneally)31 and received intratracheal instillation 
of ovalbumin (100 µg/rat) 24 hours after the last ovalbumin 
sensitization using a   Penn-Century Liquid MicroSprayer 
Aerosolizer® (Model IA-1B, Penn-Century Inc, Wyndmoor, 
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PA) with the aid of a small animal laryngoscope (Model LS-2, 
Penn-Century Inc). At one hour, 12 hours, or 23 hours before 
ovalbumin exposure, 1 mg/kg of BUD-SSMs or Pulmicort 
Respules® was administered via intratracheal instillation. At 
24 hours after ovalbumin challenge, the rats were euthanized 
in a carbon dioxide chamber, and the lungs with trachea were 
excised and lavaged.
Bronchoalveolar lavage was performed by flushing the 
airways with 5 mL of Dulbecco’s phosphate-buffered saline 
(SAFC Biosciences, Kansas City, MO) through the tracheal 
cannula. The total leukocyte cell counts and differential cell 
counts of the bronchoalveolar lavage fluid were recorded 
by a single blinded expert in a private laboratory (Pro-Lab, 
Penang, Malaysia). The total leukocyte cell counts in the 
bronchoalveolar lavage fluid were determined using a hema-
tocytometer. Cell smears (8 × 104 cells/mL) were prepared 
by centrifugation in a bronchoalveolar lavage fluid centri-
fuge at 4000 rpm for five minutes at 20ºC, after which the 
supernatants were removed and the cells were resuspended 
in Dulbecco’s phosphate-buffered saline. Differential cell 
counts of 200 leukocytes (eosinophils, lymphocytes, neu-
trophils, and macrophages) were conducted for each animal 
under light microscopy (400× magnification). Briefly, a thin 
film of resuspended cells was obtained by spreading a drop 
of the cells evenly across a clean grease-free slide. A few 
drops of Leishman’s stain (Laboratory Labchem Chemical, 
Selangor Darul Ehsan, Malaysia) were poured onto the slide, 
and after 3 minutes, 20 drops of buffered water were added. 
After a further 7 minutes, the stain was washed off with dis-
tilled water for 2–3 minutes, following which the slides were 
rinsed with tap water and stood in a rack to drain and dry 
in air. These methods are commonly employed and are fully 
described elsewhere.32,33 Percent inhibition of inflammatory 
cell infiltration into the airways was calculated according to 
the following equation:
  %
.
..
Inhibition
EE
EE
Pc ontrolG roup
Pc ontrolN control
=
−
−





 × 10 00  (7)
  %Inhibition = ((EP .cont – EGroup)/(EP .cont – EN.cont.))*100 
where EP .control, EN.control, and EGroup are inflammatory cell 
counts in bronchoalveolar lavage fluid in the positive control 
(Group C), negative control (Group B), and treatment group 
(Group D), respectively.
Statistical analysis
For statistical comparisons, analysis of variance with pairwise 
comparison and dependent and independent t-test procedures 
were used where applicable. A P value of less than 0.05 was 
considered significant for all analyses.
Results and discussion
Drug loading and maximum solubility
Budesonide was successfully incorporated into SSMs of 
PEG5000-DSPE using the coprecipitation and reconstitution 
method. The SSMs’ potential to solubilize budesonide was 
assessed with eight different budesonide concentrations rang-
ing from 430.5 to 731.85 µg/mL in 5 mM PEG5000-DSPE. 
Surprisingly, all samples at or below 605.71 ± 6.38 µg/mL 
of budesonide (drug-to-PEGylated polymer molar ratio of 
0.28) had a single uniform size distribution determined 
by photon correlation spectroscopy; a second signal was 
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Scheme 1 Sensitization, challenge and treatment protocol.
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observed above this concentration (Figure 1). For a given 
PEGylated polymer, the poorly soluble drug only solubilized 
up to a certain concentration of drug, and when the maximum 
threshold was achieved, populations of other species, namely 
sterically stabilized particles, were observed by photon cor-
relation spectroscopy (Figure 2).34 The sterically stabilized 
particles were probably stabilized by the PEG5000-DSPE on 
their surfaces, which helped the steroids form aggregates 
and thus to maximize the hydrophobic interactions and 
hydrogen bonding network with water.20,21 Formulations 
containing sterically stabilized particles were not considered 
the optimum formulation due to difficulties reproducing the 
formulations, as previously reported.20
hydrodynamic particle size and zeta 
potential of SSMs
The particle size of the final rehydrated BUD-SSMs (drug to 
PEGylated polymer molar ratio of 0.28) was 21.51 ± 1.5 nm, 
with a narrow polydispersity index (0.22 ± 0.02) that did 
not differ significantly (P . 0.05) from that observed in the 
prelyophilization process (20.45 ± 1.65), indicating formation 
of SSMs with a typical particle size of polymeric micelles 
between 10 and 100 nm.35 Due to their small size, the likeli-
hood that BUD-SSMs would undergo phagocytosis in the 
alveoli is much lower than that for micron-sized particles, 
because it has been reported that particles of less than 260 nm 
can escape phagocytosis by macrophages.36
The zeta potential measurement gives an indication of 
the stability of the colloidal system. Dispersions with a large 
negative or positive zeta potential tend to have better stabil-
ity against aggregation.37 The zeta potential of BUD-SSMs 
was −28.43 ± 1.98 mV , confirming the stability potential. 
The negative charge of the BUD-SSM formulation also gives 
it a potential advantage as a drug carrier because it has been 
reported that negatively charged particles are retained in the 
lungs more efficiently than positively charged molecules.38
Drug loading, yield, and entrapment 
efficiency of BUD-SSMs
According to the spectrophotometric and particle size analysis, 
all budesonide molecules were incorporated into the SSMs 
after lyophilization. This was supported by the lack of a signifi-
cant difference (P . 0.05) in percentage entrapment efficiency 
before (100.49 ± 1.06) and after lyophilization (100.13 ± 1.09). 
In addition, the BUD-SSM formulations had a high percentage 
yield (97.98 ± 1.95) and considerable percentage drug load-
ing (2.01% ± 0.02%). The percentage drug loading value was 
consistent with findings for other steroid formulations.39,40 In 
addition, the BUD-SSMs formed from PEG5000-DSPE were 
robust to the lyophilization conditions, with the lyophilized 
cakes having a fluffy and elegant appearance and dissolving 
easily upon reconstitution with distilled water to form clear 
and colorless solutions. This was due to the hydrophilic PEG 
polymer on the outer surface (corona), which can act as both 
a cryoprotectant and a lyoprotectant.20 A 5 mM concentration 
of PEG5000-DSPE was appropriate for lyophilization because 
high-density PEG blocks can serve as a steric barrier between 
hydrophobic cores and prevent contact between and agglom-
eration of the core materials of the micelles, as previously 
reported when using 10 mM PEG2000-DSPE.17,21
Differential scanning calorimetry study
Differential scanning calorimetry analysis was performed 
to determine the nature of the drug inside the polymer 
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Figure 1 Effect of the budesonide: PEgylated polymer molar ratio on solubilization of budesonide; PEgylated polymer molar concentration kept at 5 mM. 
Note: gray bars indicate second population signal in photon correlation spectroscopy.
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matrix (molecular dispersion or in crystallized form).41 The 
  differential scanning calorimetry thermograms for the vari-
ous budesonide samples are shown in Figure 3. Budesonide 
melted at approximately 261.58°C ± 0.32°C. The melting 
peak for PEG5000-DSPE was at 59.91°C ± 0.04°C. The peaks 
of the physical mixtures of budesonide and PEG5000-DSPE 
were approximately 256°C ± 2.27°C and 59.82°C ± 0.09°C, 
respectively, with a sharp decrease in the peak intensity 
for budesonide. Samples of the lyophilized BUD-SSMs 
gave only one peak at approximately 58.08°C ± 0.17°C for 
PEG5000-DSPE, with no endothermic budesonide peak. These 
results indicated that the physical mixing of budesonide and 
PEGylated polymer did not affect the structure of the block 
copolymer. Conversely, BUD-SSMs caused a slight but sig-
nificant (P , 0.05) downward shift in the endothermic peak 
of the PEGylated polymer, which indicated that there were 
physical interactions between budesonide and the PEGylated 
polymer. The interaction suggested that budesonide was 
molecularly dispersed in the PEGylated polymer matrix. 
The disappearance of the endothermic peak of budesonide 
at low drug concentrations in the BUD-SSMs was due to 
its complete miscibility in the molten PEGylated polymer. 
However, at higher drug ratios (physical mixture), only 
partial miscibility was achieved, and the drug only began to 
melt at 249°C ± 2.00°C. Similar results were reported in a 
study of the interaction between PEG6000 and oxazepam.42 
Zhang et al showed that the glass transition temperature of 
  paclitaxel-loaded polymeric nanoparticles from differential 
scanning calorimetry analysis was lower than that of the 
polymeric blanks, which suggested that the descent peak shift 
might be an indication that the drug is either molecularly 
dispersed in the block copolymer or distributed in the block 
copolymer in an amorphous state.43
Fourier transform infrared spectroscopy
The Fourier transform infrared spectrum of budesonide 
showed carbonyl stretching bands at 1725 and 1662 cm−1 
(Figure 4). Vibrations in the 1600–1900 cm−1 regions indi-
cated a C=O stretch. The budesonide molecule has two C=O 
groups, ie, a dihydrobenzoquinone C=O group and an acetyl 
C=O group. Typically, acetyl C=O and dihydrobenzoqui-
none C=O groups exhibit stretching bands in the regions of 
1700–1900 cm−1 and 1600–1750 cm−1, respectively. Thus, 
the bands at 1725 cm−1 and 1662 cm−1 in the budesonide 
spectrum corresponded to the nonconjugated acetyl C=O 
stretch and conjugated dihydrobenzoquinone C=O groups, 
respectively.44 In addition, there was a (OH) vibrational 
band at 3486 cm−1. The physical mixture of budesonide and 
the PEGylated polymers (PEG5000-DSPE) showed similar 
spectra. However, the lyophilized BUD-SSMs exhibited 
a small shift in the conjugated C=O stretching band from 
1662 to 1667 cm−1. This shift was caused by an altered 
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environment around the interatomic C=O bonds due to 
the solvation   process in the hydrophobic portion of the 
PEGylated   polymer. Formation of intermolecular hydrogen 
bonds between the OH group of budesonide and the C=O 
groups of the PEGylated polymer may explain this shift. 
Conversely, there was no shift in the nonconjugated C=O of 
budesonide. In addition, the vibration band of (OH) for both 
budesonide and the PEGylated polymer changed to a broad 
peak. Changes in the Fourier transform infrared spectrum of 
budesonide have also been reported by other investigators. 
Tajber et al showed that spray-dried budesonide exhibited a 
shift in the conjugated C=O stretching band when converted 
from the crystalline to the amorphous form.45 In addition, 
they found that the OH bands appeared as a broad peak 
located in the 3300–3700 cm−1 regions. They suggested a 
possible change in the environment of the conjugated C=O 
group of budesonide. As a result, no pronounced interactions 
were identified between budesonide and the PEGylated poly-
mer because the entire relevant spectral band (conjugated 
and nonconjugated C=O band) had not disappeared, which 
would indicate that the budesonide molecules were in an 
amorphous state. This result was confirmed by differential 
scanning calorimetry analysis.
Morphology of BUD-SSMs
Transmission electron microscopy is commonly used to exam-
ine nanoscopic colloids such as SSMs. The mean diameter of 
these SSMs was measured directly from randomly selected 
formulations in transmission electron microscopic images. 
The mean particle size of BUD-SSMs was 104.08 ± 27.30 nm 
(Figure 5). These measurements differed significantly from 
those obtained by photon correlation spectroscopy. This was 
due to the tendency for particles to aggregate as a result of 
the drying process during sample preparation for transmission 
electron microscopy, as also reported by other researchers.46 
Closer observation of the BUD-SSMs revealed spherical 
nanoparticles with bright and dark areas and a core-shell with 
a multivesicular appearance.
Solubility and budesonide  
release from SSMs
The equilibrium dialysis method was used to determine the 
solubility of poorly water-soluble corticosteroids because 
it enabled drug equilibration to be achieved. Furthermore, 
it overcame the inherent wetting problem of these highly 
hydrophobic powders and minimized errors associated with 
sample processing.24 The aim of the solubility study was to 
calculate the concentration that was required for the drug-
release studies under the sink condition.
Budesonide has low solubility in phosphate-buffered saline 
(21.95 ± 1.15 µg/mL) and this result was consistent with pre-
viously reported results (23 µg/mL).24 The sink condition is 
achieved if the final concentration of the drug in the   dissolution 
medium is less than 20% of the saturation   solubility of the 
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drug.47 The final concentration of budesonide after complete 
release in phosphate-buffered saline was less than 4.39 µg/mL 
and was consistent with the sink condition.
Comparison of the dissolution release profiles for 
BUD-SSMs and Pulmicort Respules® at the end of the first 
6 hours revealed that more than 90% of budesonide was 
released from Pulmicort Respules®, while less than 35% of 
budesonide was released from BUD-SSMs, with comple-
tion of release within 6 days (Figure 6). The drug release 
kinetics (Table 1) of the various preparations were evaluated 
by fitting the release data to the zero-order, first-order, and 
Higuchi equations using the DDSolver software. The most 
appropriate drug-release model was selected based on its 
highest adjusted coefficient of determination (R2 adjusted) 
value and lowest Akaike information criterion. BUD-SSMs 
best fitted the Higuchi release kinetics (P , 0.05). In 
contrast, Pulmicort Respules® followed first-order release 
kinetics (P , 0.05).
According to the Higuchi model, two possible mecha-
nisms may be involved in drug release from BUD-SSMs, ie, 
diffusion of the drug from the micelles and micelle erosion 
resulting from the degradation of the PEGylated polymer. 
In order to determine the best possible mechanism, release 
data for the BUD-SSMs were fitted to the Baker-Lonsdale 
and Hixson-Crowell models. The Baker-Lonsdale model 
best describes the release of drug incorporated in a spheri-
cal matrix following the diffusion mechanism, while the 
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Figure  5  Morphological  examinations  of  BUD-SSMs  by  transmission  electron 
microscopy. 
Note: Scale bar = 1 µm and 50 nm. 
Abbreviation: BUD-SSMs, PEg5000-DSPE polymeric micelles containing budesonide.
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Hixson-Crowell model best describes the release of drug 
from the delivery system according to the change in surface 
area and diameter of the particles over time.48–50 The results 
showed that the BUD-SSMs most closely followed the 
Baker-Lonsdale model (P , 0.05) and further supported 
the postulation that the release of budesonide from SSMs is 
more consistent with a diffusion mechanism than a matrix 
erosion mechanism. Derakhshandeh et al reported a similar 
result with 9-nitrocamptothecin-PLGA-PEG nanoparticles, 
where drug release followed the diffusion mechanism using 
the Baker-Lonsdale model.50 Abdulla et al found that the 
release profile of rifampicin-SSMs followed both the first-
order and Higuchi kinetics models.51 However, they only used 
the correlation coefficient to evaluate the goodness of fit. In 
our study, there were insignificant differences among the 
R2 adjusted values following the first-order and Higuchi equa-
tion (P . 0.05), while significant (P , 0.05) differences were 
observed among the Akaike information criterion values for 
the SSM formulations following the first-order (94.47 ± 1.67) 
and Higuchi equations (77.82 ± 3.90). Our results indicated 
that using only a single criterion to evaluate the goodness 
of fit is not sufficient. When comparing several models, the 
model with the smallest Akaike information criterion value 
is a further indication for the best goodness of fit. In addi-
tion, from a statistical point of view, the R2 adjusted value 
is regarded as a more powerful measure than the unadjusted 
coefficient of R2 determination.52
Many methods can be used to compare in vitro drug-
release profiles. For the analysis of variance (ANOVA)-based 
method, the most suitable approach is to use repeated mea-
sures ANOVA because the release data comprise repeated 
measurements collected over time during the same experi-
ment (ie, time is the repeated factor and percent drug released 
is the dependent variable). Repeated measures ANOVA 
is regarded as a more precise method than independent or 
paired t-tests.53 The one-way ANOVA method compares 
pairs of values at each time point but ignores the correlation 
between the dissolution time points (this method treats each 
time point as independent of the other, which is definitely 
not the case).54 Repeated measures ANOVA has been used 
in many studies.53,55–57
The model-dependent method evaluates the dissolution 
profiles using different model parameters (eg, t50%, release 
rate constant).53 This method cannot be used to compare 
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Figure 6 Drug-release profiles of BUD-SSMs and Pulmicort Respules®. 
Abbreviation: BUD-SSMs, PEg5000-DSPE polymeric micelles containing budesonide.
Table 1 Kinetic drug release values of different budesonide formulations
Preparations Adjusted coefficient of determination (R2 adjusted) Release rate constant
Zero- 
order
First- 
order
Higuchi Baker- 
Lonsdale  
model
Hixson- 
Crowell  
model
Zero-order  
(K0)  
(μg/hour)
First-order  
(k1)  
(per hour)
Higuchi  
(kH)  
(μg/h0.5)
Baker- 
Lonsdale
BUD-SSMs 0.76 ± 0.05 0.91 ± 0.01 0.97 ± 0.01 0.97 ± 0.01 0.88 ± 0.01 / / 9.04 ± 0.48 0.002 ± 0.00
Pulmicort  
Respules®
0.23 ± 0.30 0.98 ± 0.01 0.90 ± 0.03 / / / 0.65 ± 0.09 / /
Abbreviation: BUD-SSMs, PEg5000-DSPE polymeric micelles containing budesonide.
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the release profiles of formulations having different release 
mechanisms.58 The estimated model parameters can be 
compared statistically using the t-test.26,58 The third method 
for comparison of in vitro release is the model-independent 
method (using similarity and difference factors), but this 
was not used in this study because the coefficients of varia-
tion (release profile within batch) during the first 15 min-
utes were higher than 15%.48,54,58 When the results of our 
study were   analyzed, the repeated measures ANOVA and 
one-way ANOVA showed that there were significant differ-
ences between the percent of drug released from Pulmicort 
Respules® and BUD-SSMs. These results indicated that 
the corticosteroid-loaded SSMs successfully prolonged 
the in vitro drug release in comparison with the reference 
product.
Aerodynamic characterization
To demonstrate the ability to nebulize BUD-SSM formula-
tions, aerodynamic parameters were studied using a next 
generation impactor connected to a Pari LC nebulizer and 
comparisons were made with a commercially available 
product (Pulmicort Respules®). The aerodynamic distribution 
and characteristics of Pulmicort Respules® using the Pari LC 
nebulizer have previously been reported.23 The aerodynamic 
characteristics are shown in Table 2. The mass median aero-
dynamic diameter of BUD-SSMs was significantly smaller 
than that of the Pulmicort Respules®. These results were due 
to the formulation effect. Solutions (our formulations) and 
microsuspensions (Pulmicort Respules®) behave differently 
during nebulization. The particles in Pulmicort Respules® 
are 2–3 µm in size, as reported by other researchers, while 
the particle size of the BUD-SSMs is 20.45 ± 1.64 nm.59 The 
nebulized suspension will therefore generate larger aerosol 
droplets (ie, larger mass median aerodynamic diameter 
values) containing a smaller number of suspended particles 
(2–3 µm), whereas the aerosolized SSM droplets are smaller 
(with lower mass median aerodynamic diameter values) and 
contain many thousands of nanoparticles.60
This postulation can be proved by using simple theo-
retical calculations, as suggested elsewhere.60 The average 
droplet size produced by Pari LC nebulizers is approxi-
mately 4 to 5 µm according to the manufacturer. As such, 
the maximum particle load for an average 4.5 µm diameter 
droplet generated by the nebulizers can be estimated using 
the following calculations:
  Volume of sphere = 
 

 
4
32
3
π
d
 
(8)
where d is the diameter of the droplet in µm and π = 3.14.
The volume of an average 4.5-µm droplet produced by 
the nebulizer will be:
  = 
 

  =
4
3
45
2
47 69
3
3 πµ
.
. m  
The volume of a 2 µm Pulmicort Respules particle (the 
lowest value) will be:
  = 
 

  =
4
3
2
2
41 9
3
3 πµ . m  
The approximate volume of a 20 nm (0.02 µm) SSM 
particle will be:
  = 
 

  =×
− 4
3
00 2
2
41 91 0
3
63 πµ
.
. m  
Number of particles per 4.5-µm droplet
  =

 

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volume of 45   m droplet
volume of drug particle
. µ   (9)
The number of 2 µm Pulmicort Respules particles per 
4.5-µm droplet will be:
  = 
 

  =
47 69
41 9
79 9
.
.
.p articles per droplet  
The number of 20 nm SSM particles per 4.5-µm droplet 
will be:
  =
×

 

  =× −
47 69
41 91 0
79 91 0 6
6 .
.
.p articles per droplet  
Thus, based on the above calculations, it is possible in 
theory to pack as many as 7.99 × 106 SSM nanoparticles of 
size 20 nm into a 4.5 µm diameter droplet as opposed to only 
7.99 Pulmicort Respules particles of 4 to 5 µm diameter into 
Table  2  Aerodynamic  characteristics  of  different  budesonide 
formulations
Preparations Pulmicort Respules® BUD-SSMs
MMAD (µm) 4.48 ± 0.12 2.83 ± 0.08
gSD (µm) 2.01 ± 0.03 2.33 ± 0.04
ED (%) 39.73 ± 0.53 59.13 ± 0.19
FPF(,2.8 µm) (%) 15.48 ± 0.61 36.51 ± 0.19
FPF(,4.4 µm) (%) 29.76 ± 0.36 52.31 ± 0.25
Percent of drug remaining  
in nebulizer
56.38 ± 1.40 40.70 ± 0.63
Percent of drug deposited  
in induction port
4.39 ± 0.66 2.24 ± 0.27
Abbreviations: BUD-SSMs, PEg5000-DSPE polymeric micelles containing budesonide; 
MMAD, mass median aerodynamic; gSD, geometric standard deviation; ED, emitted 
dose; FPF, fine particle fraction.
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a similar droplet. This concept is based on the fact that there 
is a   100-fold difference in the particle diameter and that the 
volumetric manipulation is a cubic relationship. Of course, 
this situation also assumes that the particles are perfectly 
spherical in shape and does not demonstrate the effect of drug 
concentration in the formulation. All values for mass median 
aerodynamic diameter, emitted dose, fine particle fraction, 
percent of drug remaining in the nebulizer, and percent of 
drug deposited in the induction port of the   BUD-SSMs were 
significantly superior compared with Pulmicort Respules® due 
to the particle size and presence of the hydrophilic polymer 
(PEG) in the outer shell of the SSMs, which induced a repulsive 
steric interaction between the particles that could effectively 
decrease the overall adhesive forces, thereby allowing more 
efficient aerosolization and stabilizing the colloidal suspen-
sion in air.29,61,62 The geometric standard deviation values of 
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  BUD-SSMs were significantly (P , 0.05) higher than those 
of the Pulmicort Respules® due to the effect of operating the 
cascade impactor at ambient temperature, which affected 
smaller droplets more than the larger droplets generated by the 
nebulizer, and produced a wider spread of geometric standard 
deviation values, as previously reported.63 The improved aero-
dynamic performance of the BUD-SSMs leads to a decrease in 
the therapeutic dose and a reduction in systemic side effects.
Inhibitory duration of inflammatory cell 
infiltration in airways following BUD-SSMs 
and Pulmicort Respules®
Ovalbumin-sensitized animals are commonly used as an 
asthma/chronic obstructive pulmonary disease model, 
because recurrent exposure of ovalbumin in actively 
  immunized rats induces production of ovalbumin-specific 
IgE, airway hyperresponsiveness, peribronchial inflammation, 
and an increase in eosinophilia, neutrophilia,   lymphocytes,   
and macrophages in bronchioalveolar lavage fluid.64 
  Challenge with ovalbumin led to a significant inflammatory 
response (P , 0.05) in the airways of sensitized Sprague-
Dawley rats according to changes in total and differential cell 
counts of inflammatory cells in the bronchioalveolar lavage 
fluid in comparison with the untreated and sensitized groups 
(Figure 7). Treatment with Pulmicort Respules® or with 
BUD-SSMs one hour before challenge (1 mg/kg) reduced 
inflammatory cell infiltration (P , 0.05) in comparison with 
the challenged group (Figure 7). However, this inhibitory 
effect was significantly attenuated (P , 0.05) when the same 
dose of Pulmicort Respules® was administered 12 or 24 hours 
before the final challenge in comparison with the BUD-SSM 
formulations. Although the inhibitory effect was reduced, 
the results differed significantly from those of the positive 
group (P , 0.05). This is because the inhaled budesonide 
formed its fatty acid ester in the lung (budesonide-21 oleate), 
hence prolonging its   half-life in the lung to 18–20 hours 
Figure 7 Total cell counts (A), eosinophil counts (B), neutrophil counts (C), lymphocyte counts (D), and macrophage counts (E) in bronchoalveolar lavage fluid in each 
experimental group of animals. 
Notes: Error bar represents the standard error of the mean. for n = 6. Untreated, no sensitization or challenge; sensitized (negative control), multiple antigen sensitization, 
no challenge; challenged (positive control), multiple antigen sensitization with challenge. 
0
Untreated
L
y
m
p
h
o
c
y
t
e
 
c
o
u
n
t
s
i
n
 
B
A
L
F
 
(
×
1
0
4
 
c
e
l
l
s
/
m
L
)
Sensitized Challenged Pulmicort
respules®
BUD-SSMs
1 hr
12 hr
24 hr
50
100
150
200
250
300
350
0
Untreated
M
a
c
r
o
p
h
a
g
e
 
c
o
u
n
t
s
i
n
 
B
A
L
F
 
(
×
1
0
4
 
c
e
l
l
s
/
m
L
)
Sensitized Challenged Pulmicort
respules®
BUD-SSMs
1 hr
12 hr
24 hr
200
400
600
800 E
D
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2363
Pulmonary nanocarrier of budesonideInternational Journal of Nanomedicine 2011:6
and consequently showing a prolonged duration of action, 
compared with other inhaled steroids.30,65 Treatment with 
BUD-SSMs led to an extreme and prolonged (P , 0.05) 
inhibitory effect compared with Pulmicort Respules® at 12 
and 24 hours before challenge (Table 3). It should be noted 
that the antigen-induced cell infiltration in the airways was not 
affected by the placebo formulation (PEG5000-DSPE), which 
was similarly prepared by coprecipitation and reconstitution, 
and administered as a rehydrated powder ready for aerosoliza-
tion, demonstrating that the polymer had no inhibitory effect 
in this animal model (data not shown).
Because budesonide undergoes extensive hepatic inactiva-
tion (first-pass metabolism) by virtue of its molecular design, 
with a half-life of about 2.8 hours, it is likely that this inhibi-
tory effect (Figure 7) resulted from the local effect of budes-
onide in the lung.66 In addition, pulmonary absorption differs 
considerably due to the physicochemical properties of the 
drug, such as solubility.67,68 After particles deposit on the sur-
face of the airways, they are wetted and dissolve in the airway 
lining fluid. Inhaled drug particles with low solubility (such as 
budesonide in Pulmicort Respules®) take a substantial period 
of time for solubilization and partitioning between the phases 
of the airway lining, and are preferentially cleared from the air-
ways by mucociliary transport and phagocytosis. Inhaled drug 
particles with high solubility (such as budesonide in SSMs) 
enter into and dissolve in the airway lining fluid more rapidly, 
and are therefore less susceptible to mucociliary clearance.69–71 
Therefore, the microsuspension (Pulmicort Respules®) is trans-
ported out of the lungs via cilia, whereas nanoparticles can 
adhere onto the mucosal surface for a longer period and in 
that way increase the residence time of the drug in the lung.72 
Existing pharmacokinetic-pharmacodynamic studies have 
demonstrated that the pulmonary residence time of inhaled 
glucocorticoids defines their anti-inflammatory action in the 
lung, providing the opportunity for sustained-release formu-
lations to be beneficial.73 A recent pharmacokinetic study of 
paclitaxel + PEG5000-DSPE found a significantly higher area 
under the curve for paclitaxel in rat lung with a low systemic 
concentration (plasma, liver, and spleen) compared with its 
area under the curve following intravenous administration 
due to the localization of chemotherapy to the lungs, which in 
turn avoids unwanted side effects. The same study found that 
paclitaxel + PEG5000-DSPE produced similar drug levels to that 
of paclitaxel in the first hour after intratracheal inhalation, but 
that higher paclitaxel concentrations were found in the lungs 
at 12 hours compared with paclitaxel at the same time.37 These 
results confirmed the impact of SSMs as sustained-release 
formulations, from which budesonide is slowly released over 
time. As a result, BUD-SSMs inhibited airway inflammation 
in the asthma/chronic obstructive pulmonary disease model 
more effectively than the commercial dosage form. The SSM 
system for budesonide would help to prevent the side effects 
associated with systemic exposure to budesonide by decreas-
ing the dose due to the prolonged duration of action. The new 
BUD-SSM system might thus be beneficial as a treatment for 
asthma, chronic obstructive pulmonary disease, and other 
inflammatory airway diseases.
Conclusion
We successfully incorporated budesonide into SSMs of the 
PEGylated polymer, PEG5000-DSPE, with appropriate physi-
cochemical properties. The in vitro release studies indicated 
the sustained-release potential of BUD-SSMs. Furthermore, 
the BUD-SSMs showed superior aerodynamic characteristics 
compared with Pulmicort Respules®, being fine enough to 
be inhaled and reach into the deep lung tissue. The pharma-
codynamic study showed a significantly longer duration of 
inhibition of inflammatory cell infiltration in the airways of 
antigen-induced asthmatic rats which was prolonged for up 
to 24 hours, compared with Pulmicort Respules®. In general, 
the SSM system has the ability to keep budesonide at or near 
the desired pharmacological site of action and to provide 
selective and prolonged activity in the lung, thereby reducing 
systemic toxicity. Overall, the in vitro and in vivo studies of 
BUD-SSMs resulted in a good understanding of the potential 
use of SSMs as a pulmonary delivery system.
Table 3 Inhibitory duration of inflammatory cell infiltration after intratracheal instillation of different budesonide formulations
Percent inhibition Pulmicort Respules® BUD-SSMs
1 hour before  
challenge
12 hours before  
challenge
23 hours before   
challenge
1 hour before  
challenge
12 hours before  
challenge
23 hours before 
challenge
Total cell counts 84.66 ± 2.96 83.80 ± 5.54 25.06 ± 6.91 66.75 ± 5.18 91.90 ± 3.76 76.94 ± 5.11
Eosinophil counts 97.07 ± 7.94 81.33 ± 6.84 38.93 ± 10.43 72.26 ± 8.87 99.93 ± 4.84 96.41 ± 4.52
Neutrophil counts 72.38 ± 8.83 49.41 ± 8.50 13.92 ± 5.30 46.18 ± 7.44 76.80 ± 3.34 64.44 ± 6.08
Lymphocyte counts 64.69 ± 12.92 37.53 ± 4.45 55.56 ± 17.53 62.88 ± 11.80 79.26 ± 9.37 58.52 ± 17.85
Macrophage counts 88.67 ± 5.77 59.42 ± 8.79 21.24 ± 11.70 81.55 ± 5.81 96.77 ± 4.86 66.27 ± 8.27
Abbreviation: BUD-SSMs, PEg5000-DSPE polymeric micelles containing budesonide.
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